BiondVax Pharmaceuticals Ltd. (BVXV) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Jerusalem, Israel. 현재 CEO는 Amir Reichman.
BVXV 을(를) 보유 IPO 날짜 2015-05-12, 33 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $4.97M.
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
